Study reveals crucial details on skin-related side effects of cancer immune therapies
Investigators uncover 10 skin-related conditions linked to immune checkpoint inhibitors and identify which patients are more likely to develop them.
Contact Information
Boston, MAPhone: 617-726-2914
Boston, MAPhone: 617-724-5197
Yevgeniy (“Eugene”) R. Semenov, MD, MA is a board-certified dermatologist and Assistant Professor in Dermatology at Harvard Medical School with extensive experience in clinical informatics, health economics, and public health research. He received his bachelor’s in Applied Mathematics & Statistics, master’s in Applied Economics, and medical degrees from Johns Hopkins University. After graduating from medical school, Dr. Semenov pursued an internship in internal medicine at Mercy Medical Center in Baltimore, MD and residency training in Dermatology at Washington University School of Medicine in St. Louis, MO.
Dr. Semenov’s clinical expertise includes cutaneous oncology with a focus on melanoma and supportive oncodermatology. His research interests include epidemiology of melanoma and non-melanoma skin cancer with an emphasis on improving outcomes and treatment selection for patients with advanced disease. As part of this clinical and research focus, Dr. Semenov provides care to patients experiencing skin side effects from chemotherapy and immunotherapy used for the management of advanced cancers.
He has published more than 70 papers in leading dermatologic and oncologic publications, including the Journal of the American Academy of Dermatology, Journal of the American Medical Association Dermatology, Journal of Investigative Dermatology, British Journal of Dermatology, Journal for Immunotherapy of Cancer, and the Journal of the National Cancer Institute. His research has established robust multi-institutional and population-level evidence on the epidemiology, treatment options, and downstream outcomes for cutaneous immunotherapy toxicities.
Dr. Semenov is fluent in English and Russian. Dr. Semenov sees patients in our Boston location and at the MGH Cancer Center.
Clinical Interests:
Treats:
Languages:
Mass General Dermatology
50 Staniford St.
Boston, MA 02114
Phone: 617-726-2914
Mass General Cancer Center: Melanoma Program
55 Fruit Street
Boston, MA 02114
Phone: 617-724-5197
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
Investigators uncover 10 skin-related conditions linked to immune checkpoint inhibitors and identify which patients are more likely to develop them.
Results will help guide care for many patients with advanced cancer.
In this interview Kerry Reynolds, MD chats with Yevgeniy (Eugene) Semenov, MD to learn about his work in cutaneous oncology and characterizing cutaneous immune-related adverse events.
Researchers comprehensively evaluated occurrence patterns of immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors, from those affecting single organs to those involving two or more organs.
The method may help clinicians determine which patients would likely benefit from aggressive treatment even at early stages of disease.
Patients with side effects from immune checkpoint inhibitors tend to live longer.
Investigators uncover 10 skin-related conditions linked to immune checkpoint inhibitors and identify which patients are more likely to develop them.
Results will help guide care for many patients with advanced cancer.
In this interview Kerry Reynolds, MD chats with Yevgeniy (Eugene) Semenov, MD to learn about his work in cutaneous oncology and characterizing cutaneous immune-related adverse events.
Researchers comprehensively evaluated occurrence patterns of immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors, from those affecting single organs to those involving two or more organs.